Practical Guidance for the Management of Adverse Events in Patients with [KRAS.sup.G12C]-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Adagrasib (MRTX849) is a [KRAS.sup.G12C] inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with [KRAS.sup.G12C]-mutated solid tumors, including patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-04, Vol.28 (4), p.287
Hauptverfasser:	Zhang, Jun, Johnson, Melissa, Barve, Minal, Bazhenova, Lyudmila, McCarthy, Marybeth, Schwartz, Rowena, Horvath- Walsh, Elise, Velastegui, Karen, Qian, Chunlin, Spira, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Aprepitant Diarrhea Electrolytes Lung cancer, Non-small cell Lung cancer, Small cell Metastasis Palonosetron Patient compliance Pharmaceutical industry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!